PDF herunterladen
Augenheilkunde up2date 2012; 2(1): 79-96
DOI: 10.1055/s-0031-1280464
Grundlagen

© Georg Thieme Verlag KG Stuttgart · New York

Unerwünschte Arzneimittelwirkungen in der Augenheilkunde – Update 2011/12

T. Schlote1 , U. Kellner2 , 3
  • 1Tagesklinik Ambimed Basel
  • 2Zentrum seltene Netzhauterkrankungen, AugenZentrum Siegburg, MVZ ADTC Siegburg GmbH, Siegburg
  • 3RetinaScience, Bonn
Weitere Informationen

Publikationsverlauf

Publikationsdatum:
18. Januar 2012 (online)

Auch verfügbar auf
    Lizenzen und Reprints Alle Artikel dieser Rubrik

Unerwünschte Arzneimittelwirkungen (UAW) sind in der Augenheilkunde ein häufiges Ereignis. Hinzu kommt der große Bereich der Arzneimittelwechselwirkungen. Im vorliegenden Beitrag kann nicht das gesamte Spektrum möglicher UAW angesprochen werden, vielmehr werden Schwerpunkte (z. B. Glaukommittel und systemisch eingesetzte Therapeutika) und aktuelle Aspekte hervorgehoben. Hierzu gehören u. a.:

  • Wechselwirkungen zwischen Glaukommitteln und oralen Antihypertensiva

  • intraoperatives Floppy-Iris-Syndrom

  • intravitreale okuläre Medikamentenapplikation

  • UAW systemischer Medikamente an der Netzhaut und am N. opticus

Literatur

  • 1 Adelman R A, Zheng Q, Mayer H R. Persistent ocular hypertension following intravitreal bevacizumab and renibizumab injections.  J Ocul Pharmacol Ther. 2010;  105-110
    Google Scholar
  • 2 Alm A, Grierson I, Shields M B. Side effects associated with prostaglandin analog therapy.  Surv Ophthalmol. 2008;  53 93-105
    Google Scholar
  • 3 Al-Shahwan S, Al-Torbak A A, Turkmani S et al. Side-effect profile of brimonidine tartrate in children.  Ophthalmology. 2005;  112 2143
    Google Scholar
  • 4 Aragona P, Di Pietro R. Is it safe to use topical NSAIDs for corneal sensitivity in Sjögren's syndrome patients?.  Expert Opin Drug Saf. 2007;  6 33-43
    Google Scholar
  • 5 Arranz Marquez E, Teus Guezala M A, Canseco Gonzalez F. Respiratory effects of chronic therapy with latanoprost in patients with chronic obstructive pulmonary disease (COPD).  Arch Soc Esp Oftalmol. 2002;  77 553-558
    Google Scholar
  • 6 Baba T, Kubota-Taniai M, Kitahashi M et al. Two-year comparison of photodynamic therapy and intravitreal bevacizumab for treatment of myopic choroidal neovascularisation.  Br J Ophthalmol. 2010;  94 864-870
    Google Scholar
  • 7 Cardascia N, Boscia F, Furino C et al. Gentamicin-induced macular infarction in transconjunctival sutureless 25-gauge vitrectomy.  Int Ophthalmol. 2008;  28 383-385
    Google Scholar
  • 8 Casuccio A, Cillino G, Pavone C et al. Pharmacologic pupil dilation as a predicitve test for the risk for intraoperative floppy-iris syndrome.  J Cataract Refract Surg. 2011;  37 1447-1454
    Google Scholar
  • 9 Chang D F, Campbell J R. Intraoperative floppy iris syndrome associated with tamsulosin.  J Cataract Refract Surg. 2005;  31 664-673
    Google Scholar
  • 10 Coppens G, Stalmans I, Zeyen T et al. The safety and efficacy of glaucoma medication in the pediatric population.  J Pediatr Ophthalmol Strabismus. 2009;  46 12-18
    Google Scholar
  • 11 Ebenezer D, Thorne J E. Recent advances in mucous membrane pemphigoid.  Curr Opin Ophthalmol. 2008;  19 292-297
    Google Scholar
  • 12 Gianni L, Panzini I, Li S et al. International Breast Cancer Study Group. Ocular toxicity during adjuvant chemoendocrine therapy for early breast cancer: results from International Breast Cancer Study Group trials.  Cancer. 2006;  106 505-513
    Google Scholar
  • 13 Guillet V, Chevrollier A, Cassereau J et al. Ethambutol-induced optic neuropathy linked to OPA1 mutation and mitochondrial toxicity.  Mitochondrion. 2010;  10 115-124
    Google Scholar
  • 14 Haller J A, Bandello F, Belfort jr. R et al. Dexamethasone intravitreal implant in patients with macular edema related to branch or central retinal vein occlusion. Twelve-months study results.  Ophthalmology. 2011;  (Epub ahead of print)
    Google Scholar
  • 15 Jonas J B. Intravitreal triamcinolone acetonide for treatment of intraocular oedematous and neovascular diseases.  Acta Ophthalmol Scand. 2005;  83 645-663
    Google Scholar
  • 16 Kellner S, Weinitz S, Kellner U. Spectral domain optical coherence tomography detects early stages of chloroquine retinopathy similar to multifocal electroretinography, fundus autofluorescence and near-infrared autofluorescence.  Br J Ophthalmol. 2009;  93 1444-1447
    Google Scholar
  • 17 Marmor M F, Kellner U, Lai T Y Y for the American Academy of Ophthalmology et al. Revised recommendations on screening for chloroquine and hydroxchloroquine retinopathy.  Ophthalmology. 2011;  118 415-422
    Google Scholar
  • 18 Menon V, Jain D, Saxena R et al. Prospective evaluation of visual function for early detection of ethambutol toxicity.  Br J Ophthalmol. 2009;  93 1251-1254
    Google Scholar
  • 19 Mielke J. Intraokularer Druck. In: Schlote T, Kellner U, Hrsg. Unerwünschte Arzneimittelwirkungen in der Augenheilkunde. Stuttgart: Georg Thieme Verlag; 2011: 85
    Google Scholar
  • 20 Payne J F, Bergstrom C, Yan J et al. Residual triamcinolone acetonide sequested in the fovea after macular hole repair.  Retina. 2011;  31 148-53
    Google Scholar
  • 21 Purvin V, Kawasaki A, Borruat F X. Optic neuropathy in patients using amiodarone.  Arch Ophthalmol. 2006;  124 696-701
    Google Scholar
  • 22 Ramdas W D, van der Velde N, van der Cammen T F et al. Evaluation of risk of falls and orthostatic hypotension in older long-term topical beta-blocker users.  Graefes Arch Clin Exp Ophthalmol. 2009;  247 1235-1241
    Google Scholar
  • 23 Reviglio V E, Rana T S, Li Q J et al. Effects of topical nonsteroidal antiinflammatory drugs on the expression of matrix metalloproteinases in the cornea.  J Cataract Refract Surg. 2003;  29 989-997
    Google Scholar
  • 24 Rinalduzzi S, Cipriani A M, Accornero N. Topiramate and visual loss in a patient carrying a Leber hereditary optic neuropathy mutation.  Neurol Sci. 2011;  (Epub ahead of print)
    Google Scholar
  • 25 Salim S, Shields M B. Glaucoma and systemic diseases.  Surv Ophthalmol. 2010;  55 64-77
    Google Scholar
  • 26 Santanaella RM, Fraunfelder FW. Ocular adverse effects associated with systemic medications.  Drugs. 2007;  67 75-93
    Google Scholar
  • 27 Schlote T, Kellner U Hrsg.. Unerwünschte Arzneimittelwirkungen in der Augenheilkunde. 1. Aufl. Stuttgart: Georg Thieme Verlag; 2011: 4
    Google Scholar
  • 28 Schlote T, Kellner U. Nebenwirkungen von Medikamenten am Auge.  Klin Monatsbl Augenheilkd. 2009;  226 R173-R186
    Google Scholar
  • 29 Teseng J J, Vance S K, Della Torre K E et al. Sustained increased intraocular pressure related to intravitreal antivascular endothelial growth factor therapy for neovascular age-related macular degeneration.  J Glaucoma. 2011;  (Epub ahead of print)
    Google Scholar
  • 30 Urtti A, Salminen L. Minimizing systemic absorption of topically administered ophthalmic drugs.  Surv Ophthalmol. 1993;  37 435-456
    Google Scholar
  • 31 Vanhaesebrouck S, Cossey V, Cosaert K et al. Cardiorespiratory depression and hyperglycemia after unintentional ingestion of brimonidine in a neonate.  Eur J Ophthalmol. 2009;  19 694-695
    Google Scholar
  • 32 Wright T M, Freedman S F. Exposure to topical apraclonidine in children with glaucoma.  J Glaucoma. 2009;  18 395-398
    Google Scholar

Prof. Dr. med. T. Schlote

Tagesklinik Ambimed Basel

Klingentalstrasse 9

CH-4057 Basel

Schweiz

Telefon: 00 41-61/3 22-13 57

Fax: 00 41-61/3 83-14 48

eMail: praxis.schlote@bluewin.ch

      >